PM
VNDA icon

Parametrica Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Parametrica Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-21,017
Closed -$218K – 78
2014
Q3 		$218K Buy
21,017
+8,508
+68% +$112K 1.27% 43
2014
Q2 		$202K Buy
+12,509
New +$167K 1.53% 42

Other funds holding VNDA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Parametrica Management's VNDA Position: Q4 2014 in Review

Parametrica Management sold out of Vanda Pharmaceuticals (VNDA) in Q4 2014, closing a stake of 21,017 shares — an estimated $218K sold.

Parametrica Management first reported a position in VNDA in Q2 2014 and held it in 2 quarters. The position peaked at $218K in Q3 2014. 109 funds tracked by Wall St. Rank hold VNDA as of Q4 2014.

  • Parametrica Management reported no remaining Vanda Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
  • Parametrica Management sold 21,017 Vanda Pharmaceuticals shares in Q4 2014, an estimated $218K.
  • Parametrica Management first reported a position in Vanda Pharmaceuticals in Q2 2014 and held it in 2 quarters.
  • Parametrica Management's Vanda Pharmaceuticals position peaked at $218K in Q3 2014.
  • 109 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2014.

Based on Parametrica Management's 13F filing for Q4 2014, filed 9 Jan 2015.